Nwam LLC Lowers Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Nwam LLC cut its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 7.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,774 shares of the financial services provider’s stock after selling 142 shares during the period. Nwam LLC’s holdings in iShares Biotechnology ETF were worth $235,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $32,000. Canton Hathaway LLC grew its stake in iShares Biotechnology ETF by 1.0% during the 4th quarter. Canton Hathaway LLC now owns 9,961 shares of the financial services provider’s stock worth $1,317,000 after purchasing an additional 100 shares in the last quarter. Gray Foundation increased its holdings in iShares Biotechnology ETF by 25.2% during the 4th quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock worth $21,798,000 after purchasing an additional 33,179 shares during the period. IFP Advisors Inc raised its position in iShares Biotechnology ETF by 237.1% in the 4th quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after purchasing an additional 11,266 shares in the last quarter. Finally, Genesis Wealth Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at about $2,034,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $137.03 on Friday. The business has a 50-day simple moving average of $135.91 and a 200-day simple moving average of $140.62. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The company has a market cap of $6.33 billion, a PE ratio of 24.52 and a beta of 0.77.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were given a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.